Home » Business, Health & Medicine, Pharmaceuticals & Biotech, UK, World » Abilify (Schizophrenia) Market Analysis and Forecast to 2022: Radiant Insights Inc.
Radiant Insights has announced the addition of the “Abilify (Schizophrenia) – Forecast and Market Analysis to 2022” report to their offering.

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease.  

Browse Full Report with TOC at:
http://www.radiantinsights.com/research/abilify-schizophrenia-forecast-and-market-analysis-to-2022

GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM. 

To Browse Samples with TOC, click here:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare

Otsuka’s Abilify (aripiprazole) is a quinolone piperidine derivative with partial agonist properties at the D2 dopaminergic receptor. By acting as a partial agonist at this dopamine receptor subtype, Abilify presents a unique mechanism within the schizophrenia drug portfolio: partial D2 agonism modulates dopaminergic activity in areas where dopamine may be high or low, such as in the mesolimbic and mesocortical areas of the schizophrenic brain.  

Some Sample Reports by Radiant Insights

Twinrix (Prophylactic Hepatitis B Virus Vaccines) – Forecast and Market Analysis to 2022:
http://www.radiantinsights.com/research/twinrix-prophylactic-hepatitis-b-virus-vaccines-forecast-and-market-analysis-to-2022

Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV-related liver diseases. While the arrival of recombinant HBsAg vaccines has greatly reduced disease burden over the past two decades, questions surrounding vaccine uptake and effectiveness in adults, particularly in niche patient populations, still remain.

Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) – Forecast and Market Analysis to 2022:
http://www.radiantinsights.com/research/recombivax-hb-prophylactic-hepatitis-b-virus-vaccines-forecast-and-market-analysis-to-2022

GlobalData expects that the growing popularity of pediatric combination vaccines, along with the arrival of vaccines that achieve higher seroconversion rates in high-risk adults, will serve to stimulate growth in the marketplace over the forecast period. Country-specific immunization recommendations and policy implementation will be an essential metric for determining future vaccine uptake in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Canada.

Visit Here to Avail This Report at LinkedIn:
https://www.linkedin.com/pulse/abilify-schizophrenia-market-analysis-2022-radiant-insights-gaikwad


About Radiant Insights

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: sales@radiantinsights.com
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: Califonia
Country: United States
Website: http://www.radiantinsights.com/research/abilify-schizophrenia-forecast-and-market-analysis-to-2022

Comments are closed.